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Abstract
Organic chemists and metabolic engineers use largely orthogonal technologies to access small 
molecules like pharmaceuticals and commodity chemicals. As the use of biological catalysts and 
engineered organisms for chemical production grows, it is becoming increasingly evident that 
future efforts for chemical manufacture will benefit from the integration and unified expansion of 
these two fields. This review will discuss approaches that combine chemical and biological 
synthesis for small molecule production. We highlight recent advances in combining enzymatic 
and non-enzymatic catalysis in vitro, discuss the application of design principles from organic 
chemistry for engineering non-biological reactivity into enzymes, and describe the development of 
biocompatible chemistry that can be interfaced with microbial metabolism.
Introduction
Both organic chemists and metabolic engineers strive to efficiently access small molecule 
products that are essential components of our everyday lives. However, these two scientific 
disciplines rely on largely independent technologies to achieve this goal [1–5]. Over the 
course of almost two centuries, synthetic organic chemists have developed a vast array of 
reagents, catalysts, reaction conditions, and solvents to facilitate the conversion of one 
compound into another. By executing a series of these transformations in which the product 
of one reaction serves as the starting material for the subsequent reaction, chemists access 
final products of interest in a controlled, multi-step fashion. This stands in contrast to how 
organisms have evolved to synthesize small molecules. In a cellular setting, naturally 
occurring protein-based catalysts, enzymes, chemically modify small molecule metabolites 
in one reaction vessel (the cell) under highly constrained reaction conditions (ambient 
temperature in an aqueous environment). Metabolic engineers work within these in vivo 
parameters, using modern molecular biology techniques to both adjust and construct 
pathways within microorganisms to maximize production of a small molecule product of 
interest [6–8].
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As the field of metabolic engineering continues to make rapid advances, the question arises 
as to which approach may be better suited for the production of a given target molecule. 
Perhaps the most important consideration is whether or not the synthetic tools offered by 
each approach possess the reactivity and selectivity needed to access the desired product. In 
the biological realm, enzymes offer unique advantages due to their exquisite substrate 
selectivity, high catalytic efficiency, and unparalleled levels of chemo-, regio-, and 
stereocontrol. Approaches like directed evolution enable access to enzymes tailored to 
accept non-natural substrates [9–11]. Additionally, it is now possible to transfer multiple 
enzymes, and even whole metabolic pathways, into host organisms for chemical production 
[12–14]. However, even with these advances, biological catalysts still offer a relatively 
limited reaction repertoire in comparison to synthetic organic chemistry. Having to employ 
further modification of metabolic engineering products using separate chemical synthesis 
steps to reach the final target is fairly common, especially in cases when the desired small 
molecule is not of natural origin [14]. While advances in enzyme engineering will 
undoubtedly expand the breadth of organisms’ synthetic capabilities, it seems entirely 
possible that they will never be able to match those of the organic chemist.
Beyond an initial assessment of feasibility, judging the success of a synthetic effort must 
also include the following factors: the overall yield of the product, the cost of its production, 
the environmental impact of the process, and its simplicity. The Nobel prize-winning 
chemist Sir John Cornforth described the ideal synthesis as “something to be carried out in a 
disused bathtub…, the product being collected continuously through the drain hole in 100% 
purity and yield” [15]. By avoiding multi-step reaction sequences and reducing 
environmental impact (e.g. using renewable feedstocks, minimizing hazardous waste), 
fermentation processes are quite attractive relative to traditional organic synthesis when 
applying these criteria.
Since the strengths and weaknesses of organic chemistry and metabolic engineering are 
largely complementary, the question should not be which approach is superior, but how can 
we realize opportunities to combine the beneficial aspects of each field (Figure 1) [16]. This 
review will discuss recent advances in interfaced organic and biological synthesis, focusing 
on examples that truly merge tools and design principles from synthetic chemistry with 
enzymes or living organisms for the purpose of small molecule production. We will not 
include semi-synthesis, sequential “one-flask” chemocatalytic-biocatalytic cascades, and 
bioorthogonal chemistry. We will include methodology that involves simultaneous use of 
non-enzymatic and enzymatic catalysis, enzymes engineered to display non-biological 
reactivity, and biocompatible reactions that can interface with the metabolism of living 
organisms. We will also highlight key experiments that seeded interest in each area and 
outline future challenges for this developing area of research.
Combining non-enzymatic and enzymatic catalysts in vitro
Conceptually, perhaps the simplest way to unite organic and biological chemistry is to 
combine synthetic tools from both approaches in vitro. This strategy is advantageous when 
the merging of enzymatic and non-enzymatic chemistry enables a synthetic transformation 
to proceed with a selectivity or efficiency not available for the corresponding sequential 
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process. This phenomenon, known as cooperativity, was first achieved in the early 1970’s 
with Hafner and Wellner’s development of an amino acid stereoinversion reaction that 
utilized an amino acid oxidase enzyme with the non-enzymatic reagent sodium borohydride 
[17]. The combination of enzymatic and non-enzymatic catalysis has been particularly 
useful for dynamic kinetic resolutions, processes that combine an enantioselective enzymatic 
catalyst with a non-enzymatic reagent or catalyst that promotes the interconversion of 
starting material enantiomers [18–20].
Recently the labs of Hartwig and Zhao reported an advance in tandem enzymatic/non-
enzymatic catalysis: the first demonstration of cooperative catalysis involving an 
organometallic catalyst and a metalloenzyme (Figure 2A) [21••]. This transformation 
combined a ruthenium-catalyzed olefin cross-metathesis reaction with a cytochrome P450-
catalyzed epoxidation. They envisioned cooperativity could arise from the selectivity of the 
P450 for only one alkene substrate, which would be generated via cross-metathesis as part of 
an equilibrating product mixture and continually replenished by the activity of the 
metathesis catalyst. In practice, this tandem one-pot reaction provided higher yields than 
would be obtainable using the corresponding two-step sequence. Conceptually this work 
represents a significant advance and should inspire efforts to incorporate a more diverse set 
of enzymatic and non-enzymatic reactions into tandem processes.
Despite the promise of this approach, cooperative transformations combining chemical and 
biological catalysts have utilized a relatively small number of the reaction manifolds 
available to synthetic chemists. This is likely due to an inherent challenge faced in reaction 
development: mutual deactivation of the enzyme and the chemical catalyst when utilized 
together [22,23]. In the Hartwig and Zhao work, deactivation of the catalyst and enzyme was 
minimized by the use of a biphasic reaction system, but could not be completely 
circumvented. In the past year, two reports have offered alternative approaches to solving 
the deactivation problem, both of which rely on embedding a non-enzymatic transition metal 
catalyst in an environment that mimics an enzyme active site.
Bergman, Raymond, Toste, and co-workers utilized encapsulation by a supramolecular 
cluster to enable the simultaneous use of organometallic and enzymatic catalysis (Figure 2B) 
[24••]. This strategy stems from Breslow’s construction of “artificial enzymes” via 
encapsulation of a transition metal within a cyclodextrin [25]. In the context of individual 
reactions, this type of encapsulation design was known to improve lifetimes of 
organometallic catalysts, enhance their solubility in aqueous media, and prevent sensitive 
complexes from interacting with other reaction components [26,27]. Bergman, Raymond, 
Toste, and co-workers hypothesized that catalyst encapsulation could enable the use of an 
organometallic complex in combination with an enzyme. To test this idea, they designed 
tandem reaction sequences that coupled an enzymatic hydrolysis reaction with a cyclization 
catalyzed by a gold(I) species encapsulated within a tetrahedral Ga4L6 cluster (L= N, N′-
bis(2,3-dihydroxybenzoyl)-1,5-diaminonapthalene). Using this strategy, increased reactivity 
and selectivity was achieved compared to reactions with the gold(I) catalyst alone. They also 
showed that the rate of the enzymatic reaction was dramatically reduced in the absence of 
the Ga4L6 cluster, indicating that the free gold(I) catalyst was detrimental to enzyme 
function and the host complex played a protective role in the tandem process [28]. Overall, 
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this study demonstrated that supramolecular encapsulation is a viable strategy for combining 
an otherwise incompatible transition metal-catalyzed reaction with an enzyme.
The work of Hollman, Turner, Ward, and co-workers offers a complementary approach for 
facilitating the simultaneous use of non-enzymatic and enzymatic reactivity [29••]. By 
incorporating a biotin-conjugated iridium complex into the framework of the protein 
streptavidin, they generated an artificial transfer hydrogenase (ATHase) possessing 
reactivity associated with non-enzymatic, transition metal catalysts (Figure 2C). The 
ATHase could be used in tandem reactions employing a variety of enzymes, including a 
stereoselective deracemization of cyclic amines that utilized an engineered monoamine 
oxidase. In this reaction, the environment of the protein scaffold was critical for protecting 
the monoamine oxidase from deactivation; no enzymatic activity was observed in the 
presence of the unbound iridium complex. Another cascade process utilizing the ATHase 
was a coupled colorimetric assay that provided a direct readout of catalyst activity and was 
used to identify an improved ATHase variant. Coupled assays of this type could streamline 
efforts to engineer this class of organometallic hybrid catalysts via directed evolution.
These recent examples represent important advances in both the design and implementation 
of tandem enzymatic/non-enzymatic catalysis that should have a synergistic effect on future 
attempts to employ this approach in synthesis. Improved strategies for sequestering the two 
catalyst types will allow more flexibility in the types of reactivity incorporated into 
cascades. This will in turn enable the design of increasingly elegant and efficient 
cooperative reaction sequences that take full advantage of the unique aspects of organic and 
biological modes of catalysis.
Engineering enzymes to display non-biological reactivity in vitro and in 
vivo
Over the past decade, powerful advances in protein engineering technologies have fueled 
interest in extending the range of reactions amenable to biocatalysts to include those that 
have no natural antecedents [30,31]. As the development of ADHase illustrates, 
incorporating transition metals and transition metal complexes is a viable strategy for 
introducing non-enzymatic reactivity into protein scaffolds. This approach, which was 
originally pioneered by Whitesides [32], has been applied to a variety of protein scaffolds 
and transition metal complexes [33,34]. In many cases, the reactivity and selectivity of these 
hybrid catalysts do not surpass the results achieved by organic chemists. This may change 
with increasing efforts to engineer the protein scaffold for participation in the reaction 
mechanism [35–38].
An alternative approach to generating non-biological reactivity using enzyme scaffolds 
utilizes design principles and reaction manifolds from organic chemistry to guide 
reengineering of natural metalloenzyme function. Several recent papers from the Arnold 
group demonstrating the use of engineered P450BM3 mutants for unnatural carbene and 
nitrene insertion reactions illustrate the potential of this strategy [39–42]. In each case, the 
design of the enzymatic transformation was inspired by the reactivity of iron porphyrins and 
related organometallic catalysts used in organic synthesis.
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In their first report [39••], Arnold and co-workers hypothesized that cytochrome P450 
enzymes, which catalyze a variety of reactions involving oxene transfer, might also be 
capable of generating and promoting transfer of carbene intermediates in the presence of 
suitable reagents (Figure 3A). After demonstrating that wild type P450BM3 could promote 
cyclopropanation of styrene in the presence of ethyl diazoacetate under anaerobic 
conditions, they screened a library of P450BM3 mutants to evaluate whether engineering the 
protein scaffold could impact the reactivity and selectivity. Mutations that increased 
cyclopropanation activity could be combined to generate P450BM3 variants exhibiting not 
only catalytic activity comparable to nativeP450-catalysed hydroxylation reactions, but also 
enhanced diastereo- and enantioselectivity. The Arnold group applied related logic to 
engineer P450s that promote carbene insertions into N–H bonds and to develop a C-H 
amination reaction using sulfonyl azide substrates [41•,42]. Most recently, this general 
approach has been extended beyond P450s with the report of C–N bond-forming reactions 
promoted by wild-type and engineered variants of the non-heme iron(II)-dependent 
halogenase SyrB2 in the presence of both azide and nitrite anions [43•].
Arnold and co-workers have also demonstrated that the P450BM3-mediated 
cyclopropanation reaction can be utilized in vivo for whole-cell biocatalysis (Figure 3B) 
[40••]. This advance was facilitated by the discovery that a simple C400S axial ligand 
mutation in the catalytic heme domain of a P450BM3 variant could raise the resting-state 
reduction potential of the enzyme, obviating the need for exogenous reducing agents and 
allowing reduction by NADH in vivo. These C440S mutants were named ‘P411BM3’s after 
the characteristic Fe(II)-CO band in their UV-visible spectra at 411 nm. In comparison to the 
purified enzymes, P411BM3 variants displayed increased activity in the whole-cell format. 
Most impressively, the whole-cell system was capable of generating cis-ethyl 2-
phenylcyclopropane-1-carboxylate from ethyl diazoacetate and styrene in titres of 27 g L−1, 
78% isolated yield (total turnovers (TTN) = 4.88×103), and in 99% ee. The success of this 
reaction on a large scale suggests that enzymes with non-biological reactivity may be 
powerful new tools for small molecule production.
Integrating organic chemistry with cellular metabolism
While the use of biocatalysis has become increasingly important in synthetic chemistry, the 
complementary possibility of incorporating non-enzymatic reagents and catalysts from 
organic chemistry into metabolic engineering efforts has been comparatively underexplored. 
To the best of our knowledge, the use of non-enzymatic chemistry to influence microbial 
metabolism originated with Neuberg’s bisulfite-steered glycerol fermentations during the 
latter stages of the First World War [44,45]. Substantial overproduction of glycerol from 
glucose in S. cerevisiae could be achieved through the addition of sodium bisulfite to the 
fermentation. It was later found that the bisulfite anion formed a stable adduct with the 
metabolite acetaldehyde. Formation of this type of adduct is used in organic synthesis as a 
strategy for protecting aldehydes [46]. The consequence of introducing this reactivity into 
the fermentation was inhibition of acetaldehyde reduction to ethanol (Figure 4A). This 
forced accumulating NADH to be re-oxidized to NAD+ via an alternate pathway that 
generated glycerol as the primary fermentation product. This technology contributed 
significantly to the German war effort by allowing the industrial manufacture of glycerol 
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from sugar for use in the production of explosives. Since this achievement there have been 
only sporadic examples of systems that directly combine reagents from synthetic organic 
chemistry with metabolism. Mountfort and coworkers reported the hydrogenation of 
ethylene using hydrogen gas produced by the syntroph Syntrophomonas wolfei and super-
stoichiometric amounts of a heterogeneous palladium catalyst, a transformation that 
disrupted the metabolic interaction between S. wolfei and the methanogen Methanospirillum 
hungatei [47]. Other researchers have used transition metal catalysts to hydrogenate 
membrane lipids in the cyanobacterium Synechocystis sp. PCC 6803, facilitating studies of 
the biological response to changes in membrane fluidity [48].
We believe that it is time to revisit the idea of merging reactivity from organic synthesis 
with cellular metabolism. Advances in protein and metabolic engineering have greatly 
expanded the types of reactions and pathways that can be introduced into living organisms. 
At the same time, organic chemists are pioneering new approaches for accelerating catalyst 
and reaction development [49,50]. Finally, there has been a dramatic increase in the 
diversity of reaction types employed in bioorthogonal chemistry for applications like 
labeling and imaging of macromolecules [51]. With this progress as a backdrop, we have 
begun to develop biocompatible chemistry: non-enzymatic reactions that influence 
metabolism by chemically modifying small molecules in the presence of living organisms. 
This approach is distinct from bioorthogonal chemistry, which utilizes non-enzymatic 
reactions designed to neither interact nor interfere with biological systems [52–54].
There are significant technical challenges associated with the implementation of 
biocompatible chemistry, most notably the perceived mismatch between the reaction 
conditions necessary for synthetic organic chemistry (organic solvents, extreme 
temperatures and pH) and the growth conditions necessary to support living organisms 
(aqueous media, ambient temperature, neutral pH). Other challenges include the complexity 
of the intra- and extracellular environments, the limited cell-permeability of non-biological 
reagents, and the low concentrations of cellular metabolites. Despite the many obstacles 
associated with their development, biocompatible reactions would offer scientists a unique 
toolkit for manipulating and augmenting biological functions that would complement 
existing approaches.
In the context of small molecule production, biocompatible chemical transformations could 
be combined with native or engineered metabolism in vivo. These hybrid pathways could 
harness the diverse reactivity associated with non-enzymatic reactions, providing access to 
chemical structures that could not be produced through the use of enzymatic chemistry 
alone. The metabolism of microbes could be employed to generate unstable or toxic 
chemical reagents directly in reaction mixtures, potentially obviating the need to chemically 
synthesize, transport, and store large quantities of these materials. Perhaps most importantly, 
biocompatible reactions would provide a means of manipulating metabolite structures and 
concentrations in vivo that would operate independently from the central dogma. As 
metabolites mediate many cellular processes, changing their chemical structures could serve 
as way to influence biological function. For metabolic engineering, this could mean new 
approaches for influencing pathway flux and regulation that would not require genetic 
manipulation.
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A recent study from our laboratory has demonstrated the ability of biocompatible reactions 
to control biological function [55••]. We utilized non-enzymatic transition metal-catalyzed 
reactions to support the growth of auxotrophic microorganisms via the in vivo generation of 
essential nutrients from non-utilizable precursors (Figure 4B). Two different transformations 
were employed to rescue two distinct auxotrophies: a [Cp*Ru(cod)Cl]-catalyzed 
deprotection reaction that generated para-aminobenzoic acid (PABA) and an iron-catalyzed 
arene hydroxylation that formed para-hydroxybenzoic acid. In both cases, growth of the 
auxotroph was dependent on the success of the non-enzymatic reaction. While the 
efficiencies of both transformations were low, this work illustrates the dramatic influence 
that even a small change in metabolite levels can have on living organisms.
Overall, this study represents an initial step towards integrating reactions from organic 
chemistry with microbial metabolism; additional work will be required to overcome the 
substantial obstacles associated with this approach. Despite these challenges, we believe 
biocompatible chemistry will offer unique possibilities for small molecule production in the 
future.
Conclusions
The fields of organic chemistry and metabolic engineering have traditionally represented 
two independent solutions to the problem of small molecule synthesis. As recent work 
illustrates, the potential benefits of combining tools from both approaches are beginning to 
be realized. We believe that the time has come to explore in earnest the opportunities that 
exist at the intersection of these two areas of research, and we have chosen to discuss 
advances that we hope will inspire future research. We predict that more new strategies for 
small molecule production will emerge from continued research at the organic synthesis/
biological synthesis interface.
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• Efforts to combine organic and biological synthesis are increasing.
• Sequestering non-enzymatic and enzyme catalysts can overcome 
incompatibility.
• Organic chemistry inspires engineering of non-biological reactivity into 
enzymes.
• Non-enzymatic reactions can be integrated with cellular metabolism.
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Opportunities for merging chemical and biological synthesis.
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Approaches for combining enzymatic and non-enzymatic catalysis in vitro. A. A cooperative 
cross metathesis-epoxidation reaction using a ruthenium(I) catalyst and a P450BM3 enzyme. 
B. A tandem hydrolysis-cyclization sequence using a a lipase/esterase enzyme and a 
encapsulated gold(I)-catalyst. C. A dynamic kinetic resolution of cyclic amines using an 
engineered monoamine oxidase and an artificial transfer hydrogenase (ATHase) consisting 
of biotin-conjugated iridium-catalyst bound to streptavidin.
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Engineering enzymes to display non-biological reactivity using organic chemistry as 
inspiration. A. The mechanistic similarities between natural oxene transfer reactions of 
cytochrome P450 enzymes and carbene transfer reactions. B. A simple axial ligand mutation 
facilitated catalysis of cyclopropanation by P411BM3 in a whole-cell format.
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Integrating non-enzymatic chemistry with cellular metabolism. A. Neuberg’s bisulfite-
steered glycerol fermentations. The chemical reagent sodium bisulfite was used to redirect 
the natural fermentation in S. cereviseae to form glycerol. NADH = nicotinamide adenine 
dinucleotide. B. Auxotroph rescue with non-enzymatic chemistry. A Ru-catalyzed 
deprotection reaction was used to support growth of an E. coli PABA auxotroph. PABA = 
para-aminobenzoic acid.
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